SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NanoViricides - Nanobiotechnology -- Ignore unavailable to you. Want to Upgrade?

To: donpat who wrote (737)1/6/2018 9:02:01 AM
From: donpatRead Replies (2) | Respond to of 1220
 
ExThera IP:

worldwide.espacenet.com

17 results found in the Worldwide database for:

ExThera as the applicant

1. USE OF HEPARIN AND CARBOHYDRATES TO TREAT CANCER
2. METHOD FOR EXTRACORPOREAL REMOVAL OF PATHOGENIC MICROBE, AN INFLAMMATORY CELL OR AN INFLAMMATORY PROTEIN FROM BLOOD
3. METHOD FOR TREATING DRUG INTOXICATION
4. WEARABLE HEMOPERFUSION DEVICE.
5. METHOD FOR REMOVING BACTERIA FROM BLOOD USING HIGH FLOW RATE
6. METHOD FOR REMOVING CYTOKINES FROM BLOOD WITH SURFACE IMMOBILIZED POLYSACCHARIDES
7. METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA
8. METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA
9. DEVICE AND METHOD FOR RESTORATION OF CONDITION OF BLOOD
10. BLOOD FILTRATION SYSTEM CONTAINING MANNOSE COATED SUBSTRATE
11. USE OF A COMPOSITION FOR THE TREATMENT OF MUCOSITIS
12. REMOVAL OF VIRULENCE FACTOR THROUGH EXTRACORPOREAL THERAPY
13. USE OF A COMPOSITION COMPRISING CHITOSAN AND A NEGATIVELY CHARGE POLYSACCHARIDE FOR THE TREAMENT OF SALIVARY DYSFUNTION
14. Method for removing cytokines from blood with surface immobilized polysaccharides
15. DEVICE AND METHOD FOR RESTORATION OF THE CONDITION OF BLOOD
16. DEVICE AND METHOD FOR REMOVAL OF BLOOD-BORNE PATHOGENS, TOXINS AND INFLAMMATORY CYTOKINES
17. METHOD FOR REMOVAL OF MRSA FROM BLOOD
Inventor:MCCREA KEITH
WARD ROBERT
(+1)		Applicant:EXTHERA MEDICAL CORPCPC: A61K31/727
A61M1/34
A61M1/3679
(+4)
IPC: A61K31/60
A61M1/36
Publication info:ES2647577 (T3)
2017-12-22		Priority date:2012-06-13
Inventor:LARM OLLE [SE]
BERGSTROM TOMAS [SE]		Applicant:EXTHERA MEDICAL CORP [US]CPC: A61K31/70
A61M1/3679
A61M2202/0413
(+2)
IPC: A61K31/70
A61M1/36
Publication info:US2017340803 (A1)
2017-11-30		Priority date:2005-12-13
Inventor:WARD ROBERT S [US]
MCCREA KEITH R [US]		Applicant:EXTHERA MEDICAL CORP [US]CPC: A61K35/14
A61M1/3621
A61M1/3679
(+2)
IPC: A61B5/02
A61B5/145
A61B5/1468
(+1)
Publication info:WO2017151797 (A1)
2017-09-08		Priority date:2016-03-02
Inventor:ROBERT S WARD [US]
KEITH R MCCREA		Applicant:EXTHERA MEDICAL CORP [US]CPC: A61M1/1006
A61M1/101
A61M1/1012
(+7)
IPC: A61B5/00
Publication info:MX2017003723 (A)
2017-06-30		Priority date:2014-09-22
Inventor:MCCREA KEITH [US]
WARD ROBERT [US]		Applicant:EXTHERA MEDICAL CORP [US]CPC: A61M1/3679
B01J20/26
B01J20/28004
(+8)
IPC: A61M1/36
Publication info:DE15782250 (T1)
2017-08-10		Priority date:2014-04-24
Inventor:WARD ROBERT S
MCCREA KEITH R
(+2)		Applicant:EXTHERA MEDICAL CORP [US]CPC: A61K31/60
A61K31/722
A61K31/727
(+11)
IPC: A61K
A61M
Publication info:HK1177151 (A1)
2017-07-14		Priority date:2009-12-01
Inventor:WARD ROBERT S [US]
MCCREA KEITH R [US]		Applicant:EXTHERA MEDICAL CORP [US]CPC: B01D15/3828
C12Q1/24
C12Q1/70
(+6)
IPC: G01N33/543
G01N33/552
G01N33/569
Publication info:WO2017066627 (A1)
2017-04-20		Priority date:2013-11-08
Inventor:WARD ROBERT S [US]
MCCREA KEITH R [US]		Applicant:EXTHERA MEDICAL CORP [US]CPC: B01D15/3828
C12Q1/24
C12Q1/689
(+6)
IPC: C12Q1/24
C12Q1/68
C12Q1/70
Publication info:US2017073727 (A1)
2017-03-16		Priority date:2013-11-08
Inventor:OLLE LARM
BERGSTROEM THOMAS
(+4)		Applicant:EXTHERA MEDICAL CORPCPC: A61K31/70
A61M1/3679
B01J20/3272
(+1)
IPC: A61M1/36
Publication info:JP2016198551 (A)
2016-12-01		Priority date:2007-06-18
Inventor:MCCREA KEITH
WARD ROBERT
(+2)		Applicant:EXTHERA MEDICAL CORP [US]CPC: A61M1/34
A61M1/36
A61M1/3673
(+14)
IPC: B01D
Publication info:HK1216625 (A1)
2016-11-25		Priority date:2013-06-24
Inventor:WESTERMARK ANDERS [FI]
ADOLFSSON LARS [SE]
(+1)		Applicant:EXTHERA AB [SE]CPC: A61K2300/00
(+13)
IPC: A61K31/722
A61K31/727
A61K31/737
(+2)
Publication info:BRPI1009741 (A2)
2016-03-15		Priority date:2009-06-10
Inventor:KEITH MCCREA
ROBERT S WARD		Applicant:EXTHERA MEDICAL CORPCPC: A61K31/727
A61M1/362
A61M1/3679
IPC: A61K35/14
A61M1/36
A61P31/00
(+4)
Publication info:JP2015131831 (A)
2015-07-23		Priority date:2010-02-09
Inventor:LARM OLLE [SE]
ADOLFSSON LARS [SE]		Applicant:EXTHERA AB [SE]CPC: A61K2300/00
(+9)
IPC: A61K31/722
A61K31/727
A61K31/737
(+1)
Publication info:WO2015023226 (A1)
2015-02-19		Priority date:2013-08-16
Inventor:WARD ROBERT S
MCCREA KEITH R
(+2)		Applicant:EXTHERA MEDICAL CORPCPC:
IPC: A61K31/70
A61M1/36
Publication info:AU2014277852 (A1)
2015-01-22
AU2014277852 (B2)
2016-08-25		Priority date:2010-12-01
Inventor:LARM OLLE [SE]
BERGSTRÖM TOMAS [SE]
(+4)		Applicant:EXTHERA MEDICAL CORP [US]CPC: A61K8/0208
A61K8/33
A61K8/34
(+9)
IPC: A61M1/36
Publication info:US2014131276 (A1)
2014-05-15
US9669150 (B2)
2017-06-06		Priority date:2007-06-18
Inventor:MCCREA KEITH [US]
WARD ROBERT S [US]
(+1)		Applicant:EXTHERA MEDICAL CORP [US]CPC: A61B5/0002
A61B5/01
A61B5/02028
(+20)
IPC: A61B5/00
A61B5/01
A61B5/02
(+4)
Publication info:US2014012097 (A1)
2014-01-09		Priority date:2011-02-15
Inventor:LARM OLLE [SE]
MATTSBY-BALTZER INGER [SE]
(+4)		Applicant:EXTHERA MEDICAL LLC [US]
LARM OLLE [SE]
(+5)		CPC: A61M1/3679
A61M2202/203
IPC: A61M1/34
Publication info:WO2011133099 (A1)
2011-10-27		Priority date:2010-04-21



To: donpat who wrote (737)1/7/2018 10:30:06 AM
From: donpatRespond to of 1220
 
So, the FDA does have some knowledge in this area of ligand attracting
microbe traps!

Good!!!

And they are expediting the ExThera application using it.

Holy cow!!!!



To: donpat who wrote (737)1/14/2018 6:11:17 PM
From: donpatRespond to of 1220
 
FDA - Fast Track for HerpesCide

I see no reason why not!

FDA Guides to Fast Track


  • Expedited Access Pathway Program - Devices

The FDA recently published draft guidance on the Breakthrough Devices program. You can submit your comments on the draft guidance, which describes the policies that the agency intends to use to implement the program, by December 26, 2017.

On December 13, 2016, the Breakthrough Devices provisions were added to the Food, Drug, and Cosmetic Act through section 3051 of the 21st Century Cures Act. This program is intended to help patients have more timely access to devices and breakthrough technologies that provide for more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases, for which no approved or cleared treatment exists or that offer significant advantages over existing approved or cleared alternatives.

The Breakthrough Devices Program expands upon the Expedited Access Pathways (EAP) program by making future 510(k)s eligible as well as Premarket Approval applications (PMA) and De Novo device submissions. All participants previously granted EAP designation will have designation as Breakthrough Devices; no separate action is necessary.

For any questions about the Breakthrough Devices program or EAP, please contact CDRHExpeditedAccessPathway@fda.hhs.gov.

fda.gov

  • III. CONCEPTS FOR EXPEDITED PROGRAMS - Drugs

The programs that are the subject of this guidance, fast track designation, breakthrough therapy designation, accelerated approval, and priority review, are summarized in section IV and described individually in detail in sections V, VI, VII, and VIII. All four expedited programs represent efforts to address an unmet medical need in the treatment of a serious condition, which is discussed in the following paragraphs.

fda.gov


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News